Slow Response to AIDS Report Disappoints Panel

WASHINGTON—More than four months after the Institute of Medicine issued its well-publicized report on AIDS, the disease is still outpacing federal efforts to contain and understand it. "Since the report came out, a lot has happened as far as the epidemic spreading, but very little has been done to implement the strongly felt recommendations of the panel," said June Osborn, dean of the University of Michigan School of Public Health and a member of the group that prepared the report. The nec

Written byAmy Mcdonald
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

"Since the report came out, a lot has happened as far as the epidemic spreading, but very little has been done to implement the strongly felt recommendations of the panel," said June Osborn, dean of the University of Michigan School of Public Health and a member of the group that prepared the report. The necessary federal leadership is lacking, added Irving Weissman of Stanford University, who also participated in the intensive six-month study.

Samuel Thier, president of the Institute of Medicine, said he is particularly disappointed with the slow response to the committee's recommendation to coordinate research efforts among federal agencies better. But he pointed to some movement in Congress.

Sen. Pete Wilson (R-Calif.) has just introduced a bill that directs the Institute of Medicine to create a 10-member AIDS advisory panel that would report regularly to the president and Congress for at least the next five years. The panel ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies